Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfoli

Nykredit A S purchased a new position in shares of Amgen Inc. (NASDAQ: AMGN) in the undefined quarte

In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from t

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Crypto-linked equities ripped higher as Bitcoin cleared $80,000, but the S&P 500 slipped with th

Amgen has proven that it can manage market downturns fairly well. The company is also an excellent d

September's market jitters highlight defensive stocks, ADM, AMGN and SUN, with low betas, high yield

Amgen NASDAQ: AMGN outlined its growth priorities, late-stage pipeline progress and capital-allocati

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper dr

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentimen

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for

Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-S

Amgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patie

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo

Amgen NASDAQ: AMGN executives highlighted growth across its key commercial products, progress in lat

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Amgen TodayAMGNAmgen$379.72 -2.75 (-0.72%) As of 12:05 PM Eastern This is a fair market value price

Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during

Amgen provides a stable foundation with multi-billion dollar revenues and consistent cash flows. CRI

Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their secto

HSBC analyst Morten Herholdt downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and lowers the price

Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’

Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on

Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering

AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical

AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 tr

Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech a

BMO Capital analyst Evan David Seigerman downgrades Amgen (NASDAQ:AMGN) from Outperform to Market

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endp

Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintain

Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the

Amgen (NASDAQ:AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of d

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophil

Statistically significant and clinically meaningful disease and symptom improvements compared to pla

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Pla

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.91% on an annualized bas

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and raises t

Argus Research analyst Jasper Hellweg maintains Amgen (NASDAQ:AMGN) with a Buy and raises the pri

On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc.

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Mizuho analyst Salim Syed maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price targe

Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises th

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Barclays analyst Emily Field maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the pri